Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is an attractive investment opportunity due to the potential approval and commercialization of VS-7375 for 2L+ NSCLC and 2L+ PDAC, strong efficacy and manageable side effects of the drug in treating LGSOC, and potential combination treatments. However, there are risks involved with clinical trials and competition, and the company is planning a secondary offering to fund development. Overall, prospects for VS-7375 are positive, but investors must carefully watch for any setbacks in trials and competitive developments.

Bears say

Verastem is currently in the late stages of developing novel anticancer treatments, particularly focused on RAF/MEK and FAK inhibition. While preliminary anti-tumor activity has been observed in 2L-3L advanced NSCLC patients at the monotherapy dose of 600 mg, the data remain limited and only one patient has had more than 6 months of follow-up. Additionally, the expected completion of enrollment in 2026 and the evaluation of different treatment combinations suggest potential delays in bringing these treatments to market and achieving significant profitability.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.